<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fecal incontinence in adults: Management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fecal incontinence in adults: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Fecal incontinence in adults: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anthony J Lembo, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna R Spivak, DO</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nicholas J Talley, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1163369154"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Fecal incontinence has a significant social and economic impact and significantly impairs quality of life [<a href="#rid1">1-4</a>]. Fecal incontinence can contribute to the loss of the ability to live independently [<a href="#rid5">5,6</a>]. This topic will review the management of fecal incontinence in adults. Our recommendations are largely consistent with society guidelines and consensus statements [<a href="#rid7">7-9</a>]. The etiology and evaluation of fecal incontinence in adults is discussed in detail, separately. (See  <a class="medical medical_review" href="/d/html/2561.html" rel="external">"Fecal incontinence in adults: Etiology and evaluation"</a>.)</p><p class="headingAnchor" id="H1163369030"><span class="h1">TERMINOLOGY AND CLASSIFICATION</span></p><p class="bulletIndent1"><span class="glyph">●</span>Fecal incontinence is defined as the involuntary loss of solid or liquid feces.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anal incontinence is defined as the involuntary loss of solid or liquid feces or flatus.</p><p></p><p>Based on the mechanism of incontinence, fecal incontinence is divided into the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Urge incontinence is characterized by the desire to defecate, but incontinence occurs despite efforts to retain stool.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Passive incontinence is characterized by the lack of awareness of the need to defecate before the incontinent episode.</p><p></p><p class="headingAnchor" id="H898962499"><span class="h1">INITIAL MANAGEMENT</span><span class="headingEndMark"> — </span>Initial management of fecal incontinence consists of supportive care, medical therapy, and pelvic floor physical therapy</p><p class="headingAnchor" id="H1163369579"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>Supportive measures include avoiding foods or activities known to worsen symptoms and improving perianal skin hygiene. This includes avoidance of incompletely digested sugars (eg, fructose, lactose) and caffeine. Patients should be advised to keep a food and symptom diary to identify factors that cause diarrhea and incontinence. </p><p>Perianal skin should be kept clean and dry, without excessive wiping or use of astringent cleaners. Alternatively, a premoistened pad or tissue can be used for wiping. We suggest application of a barrier cream (eg, <a class="drug drug_general" data-topicid="10326" href="/d/drug information/10326.html" rel="external">zinc oxide</a>) to the perianal skin. Incontinence pads can be used to protect both skin and clothing from fecal soiling [<a href="#rid10">10</a>]. Patients who have incontinence related to cognitive dysfunction or physical debility may benefit from assistance with a regular defecation program.</p><p class="headingAnchor" id="H898962505"><span class="h2">Medical therapy</span><span class="headingEndMark"> — </span>Medical therapy should be aimed at reducing stool frequency and improving stool consistency [<a href="#rid11">11</a>]. No specific medication has been proven to be of benefit for fecal incontinence, except for antidiarrheal drugs in patients with liquid stools [<a href="#rid12">12-14</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>We begin by supplementing the diet with a bulking agent (eg, <a class="drug drug_general" data-topicid="9834" href="/d/drug information/9834.html" rel="external">psyllium</a> or <a class="drug drug_general" data-topicid="10153" href="/d/drug information/10153.html" rel="external">methylcellulose</a> 1 to 2 tablespoons per day) to improve stool consistency, especially in patients who have low-volume, loose stools. However, fiber may exacerbate incontinence in patients with decreased rectal compliance by increasing stool volume (eg, radiation proctitis, rectal stricture).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with diarrhea, it is important to treat the underlying etiology. In addition, we use the antidiarrheal agent <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a> to reduce fecal incontinence [<a href="#rid15">15</a>]. A systematic review of medical therapy for fecal incontinence identified 16 randomized studies with 558 participants [<a href="#rid12">12</a>]. In four randomized trials in which loperamide or diphenoxylate plus <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a> was compared with placebo, use of these antidiarrheals resulted in a reduction in fecal urgency, episodes of incontinence, unformed stools, and use of pads. Anorectal physiological measurements showed no clear differences between treatment periods. As compared with diphenoxylate, loperamide may be more effective at reducing urgency associated with incontinence and has fewer central nervous system side effects [<a href="#rid16">16</a>]. </p><p></p><p class="bulletIndent1">For patients who do not respond to <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a>, other antidiarrheal agents such as <a class="drug drug_general" data-topicid="101044" href="/d/drug information/101044.html" rel="external">bismuth subsalicylate</a> or bile acid binders (eg, <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a>, particularly for patients with a history of cholecystectomy or ileocolic resection), may be useful for alleviating symptoms [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with fecal impaction should be disimpacted, and concomitant constipation should be treated to prevent recurrent episodes [<a href="#rid18">18,19</a>]. (See  <a class="medical medical_review" href="/d/html/2636.html" rel="external">"Management of chronic constipation in adults", section on 'Other laxatives'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evacuation of the rectum by using suppositories or enemas may reduce overflow incontinence episodes [<a href="#rid20">20</a>]. This may be particularly helpful for patients with neurogenic bowel dysfunction due to spinal cord injury. Chronic gastrointestinal complications related to spinal cord injury and bowel management in patients with spina bifida are discussed separately. (See  <a class="medical medical_review" href="/d/html/4839.html" rel="external">"Chronic complications of spinal cord injury and disease", section on 'Gastrointestinal complications'</a> and  <a class="medical medical_review" href="/d/html/6219.html" rel="external">"Myelomeningocele (spina bifida): Management and outcome", section on 'Bowel management'</a>.) </p><p></p><p>Data comparing the efficacy of nonsurgical interventions for fecal incontinence are limited. In a trial including 300 women with ≥1 episode of fecal incontinence per month and normal stool consistency, <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a> (2 mg with ability to titrate the dose higher or lower) and six sessions of biofeedback (each intervention alone or in combination) resulted in no significant difference in fecal incontinence as compared with oral placebo and education after 24 weeks [<a href="#rid14">14</a>]. Clinical response was associated with higher symptom severity at baseline (adjusted odds ratio [aOR] 1.20, 95% CI 1.11-1.28) and being overweight compared with normal/underweight (aOR 2.15, 95% CI 1.07-4.34) [<a href="#rid21">21</a>]. </p><p class="headingAnchor" id="H1163369599"><span class="h1">SUBSEQUENT MANAGEMENT</span><span class="headingEndMark"> — </span>If initial management fails, additional evaluation with anorectal manometry and endorectal ultrasound/magnetic resonance imaging should be performed to detect functional and structural abnormalities causing fecal incontinence. Defecography is reserved for patients when anatomic abnormality is suspected to be an underlying cause of incontinence, such as rectal prolapse. However, defecography may result in a poor study if a patient is unable to hold in rectal contrast. (See  <a class="medical medical_review" href="/d/html/2561.html" rel="external">"Fecal incontinence in adults: Etiology and evaluation", section on 'Additional studies'</a>.)</p><p class="headingAnchor" id="H978871679"><span class="h2">Biofeedback</span><span class="headingEndMark"> — </span>We suggest biofeedback therapy (ie, pelvic floor rehabilitation) in patients with fecal incontinence if anorectal manometry demonstrates weakness of the external anal sphincter or decreased ability to perceive rectal distension because of nerve injury [<a href="#rid4">4,22,23</a>]. Strengthening of anal sphincter muscles and pelvic floor muscles (Kegel exercises) is useful when weak muscle tone is responsible for incontinence. Biofeedback is also useful when muscles are not coordinated and rectal compliance is decreased for cognitive retraining of the pelvic floor and the abdominal wall musculature and useful in individuals with intact anal sphincters and urge incontinence or decreased rectal sensation, which often presents as urge incontinence or overflow incontinence symptoms.</p><p>Biofeedback is not indicated in patients with the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Isolated internal anal sphincter weakness</p><p class="bulletIndent1"><span class="glyph">●</span>Overflow incontinence associated with behavioral or psychiatric disorders</p><p class="bulletIndent1"><span class="glyph">●</span>Neurological disorders associated with substantial loss of rectal sensation and/or the inability to contract the external anal sphincter</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased rectal storage capacity from resection, inflammation, or fibrosis</p><p class="bulletIndent1"><span class="glyph">●</span>Suspected or established major structural damage to continence mechanisms</p><p></p><p>Patients are guided to improve control of these muscles by electromyographic surface electrodes on an anal plug and an abdominal wall surface electrode. Biofeedback may improve fecal incontinence by enhancement of the ability to perceive rectal distension and improved coordination of the sensory and strength components that are required for continence. An effect on anal pressures has not been consistently demonstrated [<a href="#rid24">24,25</a>]. However, there are limited data to support biofeedback [<a href="#rid26">26</a>]. Although some studies have reported success rates between 38 and 100 percent, these studies have been small, have lacked a control group, have defined endpoints differently, or have had significant other methodological limitations [<a href="#rid22">22,27-31</a>].</p><p class="headingAnchor" id="H382786609"><span class="h2">Injectable anal bulking agents</span><span class="headingEndMark"> — </span>Treatment is still available at select locations, however, it is no longer recommended routinely [<a href="#rid32">32</a>]. It is hypothesized that injection of anal bulking agents (eg, dextranomer stabilized in hyaluronic acid) may enhance resting anal pressures and thereby improve fecal continence, especially in patients with passive fecal incontinence. Studies have suggested limited efficacy in the treatment of fecal incontinence [<a href="#rid33">33-36</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>A randomized trial with 206 patients compared injection with <a class="drug drug_general" data-topicid="87453" href="/d/drug information/87453.html" rel="external">dextranomer-hyaluronic acid</a> with sham injections of no substance [<a href="#rid34">34</a>]. After six months of follow-up, 71 of 136 (52 percent) patients in the active treatment arm reported a 50 percent or greater reduction in incontinence episodes, compared with 22 of 70 patients (32 percent) in the sham arm. Complications included proctalgia, rectal hemorrhage, and an abscess (14, 7, and 1 percent, respectively). No significant improvements between active and sham patients were noted in three of the four parts of the fecal incontinence quality of life scale (lifestyle, depression and self-perception, and embarrassment scales), and only a small improvement was noted in the coping and behavior scale. Only 6 percent of treated patients were fully continent at six months. A limitation of the study was that patients were not characterized clinically as to whether they had urge or passive incontinence or manometrically. The limited efficacy of dextranomer-hyaluronic acid in this study may be due to the inclusion of patients with urge incontinence [<a href="#rid37">37</a>]. Patients with urge incontinence often have external anal sphincter weakness or decreased rectal compliance, and it is biologically plausible that they are unlikely to benefit from an injectable bulking agent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An open-label study included 115 patients with fecal incontinence treated with <a class="drug drug_general" data-topicid="87453" href="/d/drug information/87453.html" rel="external">dextranomer-hyaluronic acid</a> [<a href="#rid35">35</a>]. Of the 83 individuals who completed 24-month follow-up, 63 percent experienced a ≥50 percent reduction in the total number of episodes of fecal incontinence and a significant increase in the number of incontinence-free days at 24 months, as compared with baseline (22 versus 15 days).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a trial of 126 patients with fecal incontinence who were followed for two years, clinical improvement measured by incontinence scores was not significantly different for patients who received injection with <a class="drug drug_general" data-topicid="87453" href="/d/drug information/87453.html" rel="external">dextranomer-hyaluronic acid</a> compared with patients who had sphincter training with biofeedback [<a href="#rid38">38</a>].</p><p></p><p>In 2011, <a class="drug drug_general" data-topicid="87453" href="/d/drug information/87453.html" rel="external">dextranomer-hyaluronic acid</a> gel was approved by the United States Food and Drug Administration the treatment of fecal incontinence in adult patients who have failed conservative therapy. Four 1 mL injections into the deep submucosa are given in the proximal part of the high-pressure zone of the anal canal, approximately 5 mm above the dentate line. If the response is inadequate after a minimum of four weeks, treatment can be repeated a second time.</p><p>Other injectable materials have been used to augment the internal anal sphincter (eg, silicone biomaterial, collagen, carbon-coated microbeads), but there are limited data to support their use [<a href="#rid39">39-42</a>]. </p><p class="headingAnchor" id="H294472117"><span class="h2">Anal sphincteroplasty</span><span class="headingEndMark"> — </span>Sphincteroplasty is only performed in patients with sphincter defect secondary to obstetrical injury and fecal incontinence that is refractory to conservative management or concurrent rectovaginal fistula [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/114776.html" rel="external">"Obstetric anal sphincter injury (OASIS)"</a>.)</p><p>Although short-term improvements in fecal incontinence have been reported in up to 85 percent of patients after anal sphincteroplasty, continence deteriorates thereafter, with an approximately 50 percent failure rate after 40 to 60 months [<a href="#rid43">43-47</a>]. </p><p class="headingAnchor" id="H553034908"><span class="h2">Sacral nerve stimulation</span><span class="headingEndMark"> — </span>Sacral nerve stimulation can be offered to patients who are either not candidates for biofeedback or in whom it has failed [<a href="#rid7">7</a>]. Electrical stimulation of the sacral nerve roots can improve fecal continence in patients with anal sphincter defects and those with structurally intact anal sphincters [<a href="#rid48">48-51</a>]. The exact mechanism of action of sacral nerve stimulation is not known but its effects may occur at the pelvic afferent or central level rather than primarily peripheral motor neurostimulation [<a href="#rid52">52</a>]. Sacral nerve simulation therapy is very effective in patients with weak sphincters or those with sphincter defects. It is also tried in patients with neurological disorders, low anterior resection syndrome, history of pelvic radiation, and prior spine surgery. It involves placement of a temporary electrode into the sacral foramen S3 to provide low-grade electrical stimulation. Patients who respond to a 7 to 10 day trial, with at least 50 percent improvement in symptoms, then undergo placement of a permanent electrode connected subcutaneously to an embedded stimulator [<a href="#rid48">48,49,53-61</a>]. This is the same therapy that is offered to patients with urinary incontinence and patients with both symptoms can have a dual benefit. </p><p>Sacral nerve stimulation may improve fecal continence by improving resting and squeeze pressures of the anal sphincter, rectal sensation, and increasing retrograde colonic propagating sequences [<a href="#rid57">57,62,63</a>]. The most common complications include dislocation of the electrode (12.1 percent) and infection (3.0 percent) [<a href="#rid64">64</a>]. Following stimulator implantation, a significant number of patients (19.5 percent) [<a href="#rid64">64</a>] will require surgical revision for various indications (eg, device failure, infection, electrode displacement or breakage usually if trauma to the device occurs). Battery needs to be surgically replaced every 10 years [<a href="#rid49">49,55,65</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial that included 120 patients with fecal incontinence, patients were assigned to sacral nerve stimulation or optimal medical therapy consisting of pelvic floor exercises, bulking agents, and dietary changes [<a href="#rid49">49</a>]. The permanent sacral nerve stimulator was placed into 54 of the 60 randomized patients who had demonstrated improvement during a temporary trial period. In contrast with the control group, in which there was no significant improvement in the number of episodes of fecal continence and fecal incontinence quality of life scores at 12 months follow-up, use of the sacral nerve stimulator was associated with a significant increase in both as compared with baseline. In addition, 25 patients (47 percent) who underwent sacral nerve stimulation achieved complete continence. Complications included pain at the implant site (6 percent), seroma (2 percent), and tingling in the vaginal region (9 percent). There were no septic complications requiring explantation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective, multicenter cohort of 120 patients who received implantation of a sacral nerve stimulator, 86 percent achieved greater than 50 percent reduction in incontinent episodes per week, and 40 percent had no fecal incontinence at three-year follow-up [<a href="#rid66">66,67</a>]. The most common adverse events included implant-site pain, paresthesia, change in the sensation of stimulation, and infection (28, 15 12, and 10 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, during a mean follow-up of 49 months, 36 of 87 patients (41 percent) who had undergone stimulator implantation required surgical revision [<a href="#rid65">65</a>]. Reasons for revision included infection (four patients), electrode displacement (two patients), electrode breakage (two patients), dysfunction due to an increase in impedance (four patients), pain with stimulation (seven patients), battery depletion (eight patients), and partial or total loss of clinical efficacy (nine patients).</p><p></p><p>Posterior tibial nerve stimulation (PTNS) has also been associated with short-term improvements in fecal incontinence in several series [<a href="#rid68">68-72</a>]. However, in a randomized trial in which 227 patients with fecal incontinence were assigned to PTNS or sham stimulation, there was no significant reduction in the number of episodes of fecal incontinence with PTNS [<a href="#rid71">71</a>]. However, additional studies are needed to assess the long-term efficacy of PTNS and to determine if there are sub-groups of patients who may benefit from treatment.</p><p class="headingAnchor" id="H294472365"><span class="h1">REFRACTORY SYMPTOMS</span><span class="headingEndMark"> — </span>We reserve colostomy for patients with intractable symptoms who have failed conservative and medical management and sacral nerve stimulation [<a href="#rid8">8</a>]. </p><p class="headingAnchor" id="H2960361187"><span class="h2">Colostomy</span><span class="headingEndMark"> — </span>Diversion of the fecal stream with a colostomy or ileostomy is definitive therapy for patients with intractable symptoms who have failed nonsurgical management and who have failed or are not candidates for minimally invasive surgical interventions [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/15026.html" rel="external">"Overview of surgical ostomy for fecal diversion"</a>.)</p><p class="headingAnchor" id="H304551432"><span class="h2">Other</span><span class="headingEndMark"> — </span>Stem cells and muscle progenitor cells are being studied, and there is promising data on treatments that hopefully will be available in the near future [<a href="#rid73">73</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiofrequency ablation</strong> – Radiofrequency ablation (RFA) is a procedure that involves delivering temperature-controlled radiofrequency energy to the anorectal junction to create thermal lesions in the muscle while preserving mucosal integrity. RFA is no longer recommended for treatment of fecal incontinence as long-term results have demonstrated conflicting results and limited efficacy, and randomized trials are lacking [<a href="#rid74">74-78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anal plugs</strong> (or anal insert device) – These may decrease fecal incontinence, but efficacy has not been established and for some patients, the device has been poorly tolerated [<a href="#rid79">79-84</a>]. In a randomized trial including 28 pediatric and 20 adult patients with fecal incontinence, use of an anal plug resulted in no significant difference in fecal incontinence compared with placebo while the device remained in place for most patients [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaginal insert</strong> – A vaginal insert with a pressure-regulated pump to temporarily occlude the rectum has been shown to reduce incontinence episodes by 50 percent in approximately 80 percent of women at one month [<a href="#rid85">85</a>]. When tolerated, it can be a reasonable noninvasive treatment for mild symptoms [<a href="#rid86">86</a>].</p><p></p><p class="headingAnchor" id="H909133872"><span class="h1">WHEN TO REFER</span><span class="headingEndMark"> — </span>Referral to a specialist should be considered in patients who fail to respond to initial management with supportive care and medical therapy. Such patients require additional evaluation to detect functional and structural abnormalities causing fecal incontinence and to guide subsequent management. (See  <a class="medical medical_review" href="/d/html/2561.html" rel="external">"Fecal incontinence in adults: Etiology and evaluation", section on 'Additional studies'</a> and <a class="local">'Subsequent management'</a> above.)</p><p class="headingAnchor" id="H3699410578"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116795.html" rel="external">"Society guideline links: Fecal incontinence"</a>.)</p><p class="headingAnchor" id="H898962589"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15852.html" rel="external">"Patient education: Fecal incontinence (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2007.html" rel="external">"Patient education: Fecal incontinence (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H898962595"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Fecal incontinence is defined as the involuntary loss of solid or liquid feces. Anal incontinence is defined as the involuntary loss of solid or liquid feces or flatus. Fecal urge incontinence is characterized by the desire to defecate, but incontinence occurs despite efforts to retain stool. Passive fecal incontinence is characterized by the lack of awareness of the need to defecate before the incontinent episode. (See <a class="local">'Terminology and classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initial management of fecal incontinence consists of supportive care and medical therapy. Supportive care includes avoiding foods or activities known to worsen symptoms and maintenance of perianal skin hygiene. We suggest a bulking agent and antidiarrheals in patients with fecal incontinence due to diarrhea (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Initial management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Referral to a gastroenterologist or colorectal surgeon should be considered in patients who fail to respond to initial management. Such patients should undergo additional evaluation (eg, anorectal manometry, endorectal ultrasound/magnetic resonance imaging) to detect functional and structural abnormalities causing fecal incontinence and to guide subsequent management. (See <a class="local">'When to refer'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who fail to respond to initial management, options include biofeedback, injectable anal bulking agent, sacral nerve stimulation, and anal sphincteroplasty. Biofeedback therapy for fecal incontinence should only be considered in patients with manometric evidence of weakness of the external anal sphincter or decreased ability to perceive rectal distension because of nerve injury. We reserve sacral nerve stimulation for patients who fail conservative management and pelvic floor physical therapy. (See <a class="local">'Subsequent management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fecal diversion with a colostomy or ileostomy should be reserved for patients with intractable symptoms who have failed nonsurgical management and who have failed or are not candidates for minimally invasive surgical interventions. (See <a class="local">'Refractory symptoms'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nelson R, Norton N, Cautley E, Furner S. Community-based prevalence of anal incontinence. JAMA 1995; 274:559.</a></li><li><a class="nounderline abstract_t">Sangwan YP, Coller JA. Fecal incontinence. Surg Clin North Am 1994; 74:1377.</a></li><li><a class="nounderline abstract_t">Rothbarth J, Bemelman WA, Meijerink WJ, et al. What is the impact of fecal incontinence on quality of life? Dis Colon Rectum 2001; 44:67.</a></li><li><a class="nounderline abstract_t">Landefeld CS, Bowers BJ, Feld AD, et al. National Institutes of Health state-of-the-science conference statement: prevention of fecal and urinary incontinence in adults. Ann Intern Med 2008; 148:449.</a></li><li><a class="nounderline abstract_t">Lahr CJ. Evaluation and treatment of incontinence. Pract Gastroenterol 1988; 12:27.</a></li><li><a class="nounderline abstract_t">Bharucha AE, Dunivan G, Goode PS, et al. Epidemiology, pathophysiology, and classification of fecal incontinence: state of the science summary for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) workshop. Am J Gastroenterol 2015; 110:127.</a></li><li><a class="nounderline abstract_t">Paquette IM, Varma MG, Kaiser AM, et al. The American Society of Colon and Rectal Surgeons' Clinical Practice Guideline for the Treatment of Fecal Incontinence. Dis Colon Rectum 2015; 58:623.</a></li><li><a class="nounderline abstract_t">Bharucha AE, Rao SSC, Shin AS. Surgical Interventions and the Use of Device-Aided Therapy for the Treatment of Fecal Incontinence and Defecatory Disorders. Clin Gastroenterol Hepatol 2017; 15:1844.</a></li><li><a class="nounderline abstract_t">Wald A, Bharucha AE, Limketkai B, et al. ACG Clinical Guidelines: Management of Benign Anorectal Disorders. Am J Gastroenterol 2021; 116:1987.</a></li><li><a class="nounderline abstract_t">Wald A, Bharucha AE, Cosman BC, Whitehead WE. ACG clinical guideline: management of benign anorectal disorders. Am J Gastroenterol 2014; 109:1141.</a></li><li><a class="nounderline abstract_t">Bharucha AE, Knowles CH, Mack I, et al. Faecal incontinence in adults. Nat Rev Dis Primers 2022; 8:53.</a></li><li><a class="nounderline abstract_t">Omar MI, Alexander CE. Drug treatment for faecal incontinence in adults. Cochrane Database Syst Rev 2013; :CD002116.</a></li><li><a class="nounderline abstract_t">Bharucha AE, Fletcher JG, Camilleri M, et al. Effects of clonidine in women with fecal incontinence. Clin Gastroenterol Hepatol 2014; 12:843.</a></li><li><a class="nounderline abstract_t">Jelovsek JE, Markland AD, Whitehead WE, et al. Controlling faecal incontinence in women by performing anal exercises with biofeedback or loperamide: a randomised clinical trial. Lancet Gastroenterol Hepatol 2019; 4:698.</a></li><li><a class="nounderline abstract_t">Markland AD, Burgio KL, Whitehead WE, et al. Loperamide Versus Psyllium Fiber for Treatment of Fecal Incontinence: The Fecal Incontinence Prescription (Rx) Management (FIRM) Randomized Clinical Trial. Dis Colon Rectum 2015; 58:983.</a></li><li><a class="nounderline abstract_t">Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology 1980; 79:1272.</a></li><li><a class="nounderline abstract_t">Remes-Troche JM, Ozturk R, Philips C, et al. Cholestyramine--a useful adjunct for the treatment of patients with fecal incontinence. Int J Colorectal Dis 2008; 23:189.</a></li><li><a class="nounderline abstract_t">Wrenn K. Fecal impaction. N Engl J Med 1989; 321:658.</a></li><li><a class="nounderline abstract_t">Ryan D, Wilson A, Muir TS, Judge TG. The reduction of faecal incontinence by the use of "Duphalac" in geriatric patients. Curr Med Res Opin 1974; 2:329.</a></li><li><a class="nounderline abstract_t">Velde SV, Biervliet SV, Bruyne RD, Winckel MV. A systematic review on bowel management and the success rate of the various treatment modalities in spina bifida patients. Spinal Cord 2013; 51:873.</a></li><li><a class="nounderline abstract_t">Richter HE, Jelovsek JE, Iyer P, et al. Characteristics Associated With Clinically Important Treatment Responses in Women Undergoing Nonsurgical Therapy for Fecal Incontinence. Am J Gastroenterol 2020; 115:115.</a></li><li><a class="nounderline abstract_t">Madoff RD, Parker SC, Varma MG, Lowry AC. Faecal incontinence in adults. Lancet 2004; 364:621.</a></li><li><a class="nounderline abstract_t">Rao SS, Bharucha AE, Chiarioni G, et al. Functional Anorectal Disorders. Gastroenterology 2016.</a></li><li><a class="nounderline abstract_t">Norton C, Chelvanayagam S, Wilson-Barnett J, et al. Randomized controlled trial of biofeedback for fecal incontinence. Gastroenterology 2003; 125:1320.</a></li><li><a class="nounderline abstract_t">Heymen S, Scarlett Y, Jones K, et al. Randomized controlled trial shows biofeedback to be superior to pelvic floor exercises for fecal incontinence. Dis Colon Rectum 2009; 52:1730.</a></li><li><a class="nounderline abstract_t">Norton C, Hosker G, Brazzelli M. Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults. Cochrane Database Syst Rev 2000; :CD002111.</a></li><li><a class="nounderline abstract_t">Ko CY, Tong J, Lehman RE, et al. Biofeedback is effective therapy for fecal incontinence and constipation. Arch Surg 1997; 132:829.</a></li><li><a class="nounderline abstract_t">Ryn AK, Morren GL, Hallböök O, Sjödahl R. Long-term results of electromyographic biofeedback training for fecal incontinence. Dis Colon Rectum 2000; 43:1262.</a></li><li><a class="nounderline abstract_t">Guillemot F, Bouche B, Gower-Rousseau C, et al. Biofeedback for the treatment of fecal incontinence. Long-term clinical results. Dis Colon Rectum 1995; 38:393.</a></li><li><a class="nounderline abstract_t">MacLeod JH. Management of anal incontinence by biofeedback. Gastroenterology 1987; 93:291.</a></li><li><a class="nounderline abstract_t">Byrne CM, Solomon MJ, Young JM, et al. Biofeedback for fecal incontinence: short-term outcomes of 513 consecutive patients and predictors of successful treatment. Dis Colon Rectum 2007; 50:417.</a></li><li><a class="nounderline abstract_t">Bordeianou LG, Thorsen AJ, Keller DS, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Fecal Incontinence. Dis Colon Rectum 2023; 66:647.</a></li><li><a class="nounderline abstract_t">Maeda Y, Laurberg S, Norton C. Perianal injectable bulking agents as treatment for faecal incontinence in adults. Cochrane Database Syst Rev 2013; :CD007959.</a></li><li><a class="nounderline abstract_t">Graf W, Mellgren A, Matzel KE, et al. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial. Lancet 2011; 377:997.</a></li><li><a class="nounderline abstract_t">La Torre F, de la Portilla F. Long-term efficacy of dextranomer in stabilized hyaluronic acid (NASHA/Dx) for treatment of faecal incontinence. Colorectal Dis 2013; 15:569.</a></li><li class="breakAll">https://www.clinicaltrials.gov/ct2/show/record/NCT01647906 (Accessed on July 06, 2020).</li><li><a class="nounderline abstract_t">Wald A. New treatments for fecal incontinence: update for the gastroenterologist. Clin Gastroenterol Hepatol 2014; 12:1783.</a></li><li><a class="nounderline abstract_t">Dehli T, Stordahl A, Vatten LJ, et al. Sphincter training or anal injections of dextranomer for treatment of anal incontinence: a randomized trial. Scand J Gastroenterol 2013; 48:302.</a></li><li><a class="nounderline abstract_t">Tjandra JJ, Lim JF, Hiscock R, Rajendra P. Injectable silicone biomaterial for fecal incontinence caused by internal anal sphincter dysfunction is effective. Dis Colon Rectum 2004; 47:2138.</a></li><li><a class="nounderline abstract_t">Stojkovic SG, Lim M, Burke D, et al. Intra-anal collagen injection for the treatment of faecal incontinence. Br J Surg 2006; 93:1514.</a></li><li><a class="nounderline abstract_t">Altomare DF, La Torre F, Rinaldi M, et al. Carbon-coated microbeads anal injection in outpatient treatment of minor fecal incontinence. Dis Colon Rectum 2008; 51:432.</a></li><li><a class="nounderline abstract_t">Sarveazad A, Newstead GL, Mirzaei R, et al. A new method for treating fecal incontinence by implanting stem cells derived from human adipose tissue: preliminary findings of a randomized double-blind clinical trial. Stem Cell Res Ther 2017; 8:40.</a></li><li><a class="nounderline abstract_t">Cheung O, Wald A. Review article: the management of pelvic floor disorders. Aliment Pharmacol Ther 2004; 19:481.</a></li><li><a class="nounderline abstract_t">Kamm MA. Faecal incontinence. BMJ 1998; 316:528.</a></li><li><a class="nounderline abstract_t">Malouf AJ, Norton CS, Engel AF, et al. Long-term results of overlapping anterior anal-sphincter repair for obstetric trauma. Lancet 2000; 355:260.</a></li><li><a class="nounderline abstract_t">Grey BR, Sheldon RR, Telford KJ, Kiff ES. Anterior anal sphincter repair can be of long term benefit: a 12-year case cohort from a single surgeon. BMC Surg 2007; 7:1.</a></li><li><a class="nounderline abstract_t">Spivak AR, Hull TL. The role of sphincter repair for fecal incontinence. Annals of Laparoscopic and Endoscopic Surgery 2022; 7.</a></li><li><a class="nounderline abstract_t">Mowatt G, Glazener C, Jarrett M. Sacral nerve stimulation for faecal incontinence and constipation in adults. Cochrane Database Syst Rev 2007; :CD004464.</a></li><li><a class="nounderline abstract_t">Tjandra JJ, Chan MK, Yeh CH, Murray-Green C. Sacral nerve stimulation is more effective than optimal medical therapy for severe fecal incontinence: a randomized, controlled study. Dis Colon Rectum 2008; 51:494.</a></li><li><a class="nounderline abstract_t">Boyle DJ, Knowles CH, Lunniss PJ, et al. Efficacy of sacral nerve stimulation for fecal incontinence in patients with anal sphincter defects. Dis Colon Rectum 2009; 52:1234.</a></li><li><a class="nounderline abstract_t">Thaha MA, Abukar AA, Thin NN, et al. Sacral nerve stimulation for faecal incontinence and constipation in adults. Cochrane Database Syst Rev 2015; :CD004464.</a></li><li><a class="nounderline abstract_t">Carrington EV, Evers J, Grossi U, et al. A systematic review of sacral nerve stimulation mechanisms in the treatment of fecal incontinence and constipation. Neurogastroenterol Motil 2014; 26:1222.</a></li><li><a class="nounderline abstract_t">Gourcerol G, Gallas S, Michot F, et al. Sacral nerve stimulation in fecal incontinence: are there factors associated with success? Dis Colon Rectum 2007; 50:3.</a></li><li><a class="nounderline abstract_t">Hetzer FH, Bieler A, Hahnloser D, et al. Outcome and cost analysis of sacral nerve stimulation for faecal incontinence. Br J Surg 2006; 93:1411.</a></li><li><a class="nounderline abstract_t">Leroi AM, Parc Y, Lehur PA, et al. Efficacy of sacral nerve stimulation for fecal incontinence: results of a multicenter double-blind crossover study. Ann Surg 2005; 242:662.</a></li><li><a class="nounderline abstract_t">Rosen HR, Urbarz C, Holzer B, et al. Sacral nerve stimulation as a treatment for fecal incontinence. Gastroenterology 2001; 121:536.</a></li><li><a class="nounderline abstract_t">Matzel KE, Stadelmaier U, Hohenfellner M, Gall FP. Electrical stimulation of sacral spinal nerves for treatment of faecal incontinence. Lancet 1995; 346:1124.</a></li><li><a class="nounderline abstract_t">Jarrett ME, Matzel KE, Christiansen J, et al. Sacral nerve stimulation for faecal incontinence in patients with previous partial spinal injury including disc prolapse. Br J Surg 2005; 92:734.</a></li><li><a class="nounderline abstract_t">Uludağ O, Koch SM, van Gemert WG, et al. Sacral neuromodulation in patients with fecal incontinence: a single-center study. Dis Colon Rectum 2004; 47:1350.</a></li><li><a class="nounderline abstract_t">Matzel KE, Kamm MA, Stösser M, et al. Sacral spinal nerve stimulation for faecal incontinence: multicentre study. Lancet 2004; 363:1270.</a></li><li><a class="nounderline abstract_t">Rasmussen OO, Buntzen S, Sørensen M, et al. Sacral nerve stimulation in fecal incontinence. Dis Colon Rectum 2004; 47:1158.</a></li><li><a class="nounderline abstract_t">Kenefick NJ, Nicholls RJ, Cohen RG, Kamm MA. Permanent sacral nerve stimulation for treatment of idiopathic constipation. Br J Surg 2002; 89:882.</a></li><li><a class="nounderline abstract_t">Patton V, Wiklendt L, Arkwright JW, et al. The effect of sacral nerve stimulation on distal colonic motility in patients with faecal incontinence. Br J Surg 2013; 100:959.</a></li><li><a class="nounderline abstract_t">Duelund-Jakobsen J, Lehur PA, Lundby L, et al. Sacral nerve stimulation for faecal incontinence - efficacy confirmed from a two-centre prospectively maintained database. Int J Colorectal Dis 2016; 31:421.</a></li><li><a class="nounderline abstract_t">Faucheron JL, Voirin D, Badic B. Sacral nerve stimulation for fecal incontinence: causes of surgical revision from a series of 87 consecutive patients operated on in a single institution. Dis Colon Rectum 2010; 53:1501.</a></li><li><a class="nounderline abstract_t">Wexner SD, Coller JA, Devroede G, et al. Sacral nerve stimulation for fecal incontinence: results of a 120-patient prospective multicenter study. Ann Surg 2010; 251:441.</a></li><li><a class="nounderline abstract_t">Mellgren A, Wexner SD, Coller JA, et al. Long-term efficacy and safety of sacral nerve stimulation for fecal incontinence. Dis Colon Rectum 2011; 54:1065.</a></li><li><a class="nounderline abstract_t">George AT, Kalmar K, Sala S, et al. Randomized controlled trial of percutaneous versus transcutaneous posterior tibial nerve stimulation in faecal incontinence. Br J Surg 2013; 100:330.</a></li><li><a class="nounderline abstract_t">Queralto M, Portier G, Cabarrot PH, et al. Preliminary results of peripheral transcutaneous neuromodulation in the treatment of idiopathic fecal incontinence. Int J Colorectal Dis 2006; 21:670.</a></li><li><a class="nounderline abstract_t">Govaert B, Pares D, Delgado-Aros S, et al. A prospective multicentre study to investigate percutaneous tibial nerve stimulation for the treatment of faecal incontinence. Colorectal Dis 2010; 12:1236.</a></li><li><a class="nounderline abstract_t">Knowles CH, Horrocks EJ, Bremner SA, et al. Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of faecal incontinence in adults (CONFIDeNT): a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial. Lancet 2015; 386:1640.</a></li><li><a class="nounderline abstract_t">Peña Ros E, Parra Baños PA, Benavides Buleje JA, et al. Short-term outcome of percutaneous posterior tibial nerve stimulation (PTNS) for the treatment of faecal incontinence. Tech Coloproctol 2016; 20:19.</a></li><li><a class="nounderline abstract_t">Balaphas A, Meyer J, Meier RPH, et al. Cell Therapy for Anal Sphincter Incontinence: Where Do We Stand? Cells 2021; 10.</a></li><li><a class="nounderline abstract_t">Takahashi T, Garcia-Osogobio S, Valdovinos MA, et al. Radio-frequency energy delivery to the anal canal for the treatment of fecal incontinence. Dis Colon Rectum 2002; 45:915.</a></li><li><a class="nounderline abstract_t">Takahashi-Monroy T, Morales M, Garcia-Osogobio S, et al. SECCA procedure for the treatment of fecal incontinence: results of five-year follow-up. Dis Colon Rectum 2008; 51:355.</a></li><li><a class="nounderline abstract_t">Ruiz D, Pinto RA, Hull TL, et al. Does the radiofrequency procedure for fecal incontinence improve quality of life and incontinence at 1-year follow-up? Dis Colon Rectum 2010; 53:1041.</a></li><li><a class="nounderline abstract_t">Efron JE, Corman ML, Fleshman J, et al. Safety and effectiveness of temperature-controlled radio-frequency energy delivery to the anal canal (Secca procedure) for the treatment of fecal incontinence. Dis Colon Rectum 2003; 46:1606.</a></li><li><a class="nounderline abstract_t">Kim DW, Yoon HM, Park JS, et al. Radiofrequency energy delivery to the anal canal: is it a promising new approach to the treatment of fecal incontinence? Am J Surg 2009; 197:14.</a></li><li><a class="nounderline abstract_t">Deutekom M, Dobben AC. Plugs for containing faecal incontinence. Cochrane Database Syst Rev 2012; :CD005086.</a></li><li><a class="nounderline abstract_t">Lukacz ES, Segall MM, Wexner SD. Evaluation of an Anal Insert Device for the Conservative Management of Fecal Incontinence. Dis Colon Rectum 2015; 58:892.</a></li><li><a class="nounderline abstract_t">Bond C, Youngson G, MacPherson I, et al. Anal plugs for the management of fecal incontinence in children and adults: a randomized control trial. J Clin Gastroenterol 2007; 41:45.</a></li><li><a class="nounderline abstract_t">Van Winckel M, Van Biervliet S, Van Laecke E, Hoebeke P. Is an anal plug useful in the treatment of fecal incontinence in children with spina bifida or anal atresia? J Urol 2006; 176:342.</a></li><li><a class="nounderline abstract_t">Norton C, Kamm MA. Anal plug for faecal incontinence. Colorectal Dis 2001; 3:323.</a></li><li><a class="nounderline abstract_t">Pfrommer W, Holschneider AM, Löffler N, et al. A new polyurethane anal plug in the treatment of incontinence after anal atresia repair. Eur J Pediatr Surg 2000; 10:186.</a></li><li><a class="nounderline abstract_t">Richter HE, Matthews CA, Muir T, et al. A vaginal bowel-control system for the treatment of fecal incontinence. Obstet Gynecol 2015; 125:540.</a></li><li><a class="nounderline abstract_t">Richter HE, Dunivan G, Brown HW, et al. A 12-Month Clinical Durability of Effectiveness and Safety Evaluation of a Vaginal Bowel Control System for the Nonsurgical Treatment of Fecal Incontinence. Female Pelvic Med Reconstr Surg 2019; 25:113.</a></li></ol></div><div id="topicVersionRevision">Topic 96913 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7629985" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Community-based prevalence of anal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7985072" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Fecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11805565" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : What is the impact of fecal incontinence on quality of life?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18268289" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : National Institutes of Health state-of-the-science conference statement: prevention of fecal and urinary incontinence in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Evaluation and treatment of incontinence</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25533002" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epidemiology, pathophysiology, and classification of fecal incontinence: state of the science summary for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26200676" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The American Society of Colon and Rectal Surgeons' Clinical Practice Guideline for the Treatment of Fecal Incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28838787" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Surgical Interventions and the Use of Device-Aided Therapy for the Treatment of Fecal Incontinence and Defecatory Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34618700" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : ACG Clinical Guidelines: Management of Benign Anorectal Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25022811" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : ACG clinical guideline: management of benign anorectal disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35948559" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Faecal incontinence in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23757096" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Drug treatment for faecal incontinence in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23891925" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effects of clonidine in women with fecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31320277" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Controlling faecal incontinence in women by performing anal exercises with biofeedback or loperamide: a randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26347971" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Loperamide Versus Psyllium Fiber for Treatment of Fecal Incontinence: The Fecal Incontinence Prescription (Rx) Management (FIRM) Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7002706" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17938939" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cholestyramine--a useful adjunct for the treatment of patients with fecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2671728" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Fecal impaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4448099" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The reduction of faecal incontinence by the use of "Duphalac" in geriatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24126852" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A systematic review on bowel management and the success rate of the various treatment modalities in spina bifida patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31895722" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Characteristics Associated With Clinically Important Treatment Responses in Women Undergoing Nonsurgical Therapy for Fecal Incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15313364" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Faecal incontinence in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27144630" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Functional Anorectal Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14598248" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Randomized controlled trial of biofeedback for fecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19966605" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Randomized controlled trial shows biofeedback to be superior to pelvic floor exercises for fecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10796859" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9267265" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Biofeedback is effective therapy for fecal incontinence and constipation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11005494" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-term results of electromyographic biofeedback training for fecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7720447" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Biofeedback for the treatment of fecal incontinence. Long-term clinical results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3596165" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Management of anal incontinence by biofeedback.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17476558" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Biofeedback for fecal incontinence: short-term outcomes of 513 consecutive patients and predictors of successful treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Fecal Incontinence</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23450581" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Perianal injectable bulking agents as treatment for faecal incontinence in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21420555" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23374680" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Long-term efficacy of dextranomer in stabilized hyaluronic acid (NASHA/Dx) for treatment of faecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23374680" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Long-term efficacy of dextranomer in stabilized hyaluronic acid (NASHA/Dx) for treatment of faecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24534548" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : New treatments for fecal incontinence: update for the gastroenterologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23298304" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Sphincter training or anal injections of dextranomer for treatment of anal incontinence: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15657666" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Injectable silicone biomaterial for fecal incontinence caused by internal anal sphincter dysfunction is effective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17048278" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Intra-anal collagen injection for the treatment of faecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18204878" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Carbon-coated microbeads anal injection in outpatient treatment of minor fecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28222801" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A new method for treating fecal incontinence by implanting stem cells derived from human adipose tissue: preliminary findings of a randomized double-blind clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14987317" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Review article: the management of pelvic floor disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9501717" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Faecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10675072" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Long-term results of overlapping anterior anal-sphincter repair for obstetric trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17217528" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Anterior anal sphincter repair can be of long term benefit: a 12-year case cohort from a single surgeon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The role of sphincter repair for fecal incontinence</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17636759" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sacral nerve stimulation for faecal incontinence and constipation in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18278532" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Sacral nerve stimulation is more effective than optimal medical therapy for severe fecal incontinence: a randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19571698" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Efficacy of sacral nerve stimulation for fecal incontinence in patients with anal sphincter defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26299888" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Sacral nerve stimulation for faecal incontinence and constipation in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25167953" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A systematic review of sacral nerve stimulation mechanisms in the treatment of fecal incontinence and constipation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17080278" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Sacral nerve stimulation in fecal incontinence: are there factors associated with success?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17022014" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Outcome and cost analysis of sacral nerve stimulation for faecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16244539" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Efficacy of sacral nerve stimulation for fecal incontinence: results of a multicenter double-blind crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11522736" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Sacral nerve stimulation as a treatment for fecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7475602" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Electrical stimulation of sacral spinal nerves for treatment of faecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15838899" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Sacral nerve stimulation for faecal incontinence in patients with previous partial spinal injury including disc prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15484349" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Sacral neuromodulation in patients with fecal incontinence: a single-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15094271" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Sacral spinal nerve stimulation for faecal incontinence: multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15216409" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Sacral nerve stimulation in fecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12081738" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Permanent sacral nerve stimulation for treatment of idiopathic constipation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23536312" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The effect of sacral nerve stimulation on distal colonic motility in patients with faecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26490052" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Sacral nerve stimulation for faecal incontinence - efficacy confirmed from a two-centre prospectively maintained database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20940598" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Sacral nerve stimulation for fecal incontinence: causes of surgical revision from a series of 87 consecutive patients operated on in a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20160636" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Sacral nerve stimulation for fecal incontinence: results of a 120-patient prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21825885" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Long-term efficacy and safety of sacral nerve stimulation for fecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23300071" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Randomized controlled trial of percutaneous versus transcutaneous posterior tibial nerve stimulation in faecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16331464" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Preliminary results of peripheral transcutaneous neuromodulation in the treatment of idiopathic fecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19674028" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A prospective multicentre study to investigate percutaneous tibial nerve stimulation for the treatment of faecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26293315" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of faecal incontinence in adults (CONFIDeNT): a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26499791" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Short-term outcome of percutaneous posterior tibial nerve stimulation (PTNS) for the treatment of faecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34440855" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Cell Therapy for Anal Sphincter Incontinence: Where Do We Stand?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12130880" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Radio-frequency energy delivery to the anal canal for the treatment of fecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18204954" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : SECCA procedure for the treatment of fecal incontinence: results of five-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20551757" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Does the radiofrequency procedure for fecal incontinence improve quality of life and incontinence at 1-year follow-up?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14668584" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Safety and effectiveness of temperature-controlled radio-frequency energy delivery to the anal canal (Secca procedure) for the treatment of fecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18614149" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Radiofrequency energy delivery to the anal canal: is it a promising new approach to the treatment of fecal incontinence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22513927" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Plugs for containing faecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26252852" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Evaluation of an Anal Insert Device for the Conservative Management of Fecal Incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17198065" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Anal plugs for the management of fecal incontinence in children and adults: a randomized control trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16753439" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Is an anal plug useful in the treatment of fecal incontinence in children with spina bifida or anal atresia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12790954" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Anal plug for faecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10982049" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A new polyurethane anal plug in the treatment of incontinence after anal atresia repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25730213" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A vaginal bowel-control system for the treatment of fecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30807411" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A 12-Month Clinical Durability of Effectiveness and Safety Evaluation of a Vaginal Bowel Control System for the Nonsurgical Treatment of Fecal Incontinence.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
